Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

79.97 -1.08 (-1.33%)
Streaming Delayed Price Updated: 3:44 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Why Novo Nordisk Stock Pumped Higher on Thursday
Via The Motley Fool
Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking
The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies. 
Via Stocktwits
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills
Nvidia teams up with Novo Nordisk and IQVIA to boost AI-powered drug development and streamline complex pharmaceutical workflows. 
Via Benzinga
4 Dividend Stocks to Double Up on Right Now
The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
Via The Motley Fool
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned. 
Via Benzinga
Nvidia Extends AI Reach In Europe With Alliances
Nvidia announced a flurry of alliances with European companies and governments that extend its influence in AI across the continent. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. 
Via Stocktwits
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity. 
Via Benzinga
Why Novo Nordisk Stock Just Popped
Novo Nordisk stock has multiple catalysts that could soon reverse is slide. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Weight Loss Drug Stocks That Are Screaming Buys in June
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
Why Novo Nordisk Stock Eked Out a Win on Monday
Via The Motley Fool
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch
The company is planning to soon begin combination studies, testing two of its drugs in weight loss. 
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Via The Motley Fool
Topics Supply Chain
Exposures Supply Chain
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin? 
Via MarketBeat
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide. 
Via Investor's Business Daily
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer. 
Via Benzinga
Novo Nordisk Stock: Is It Still a Smart Buy?
Via The Motley Fool
Should You Invest $1,000 in Eli Lilly today?
Via The Motley Fool
What's Going On With Novo Nordisk Shares Today?
Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney... 
Via Benzinga
Florida Rep. Scott Franklin Bought Up to $15K Worth of Union Pacific Stock
Via Benzinga
Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target
Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.